Patient apps – a step forward in the diagnosis and treatment of endometriosis?

There are tens of thousands of fitness and health apps designed to address our desire to monitor our bodily functions. A significant portion of these apps aims to assist patients dealing with specific medical conditions in tracking vital data crucial for diagnosis, monitoring, or treatment.

It's heartening to observe that there's a growing focus on the management of endometriosis as well. A recent article authored by Karima Moumane and Ali Idri comprehensively examines and assesses the functionalities and features of 25 mobile apps specifically designed for endometriosis management and monitoring.

There is much to be gained from recording patient data in the context of endometriosis. To begin with, early symptom monitoring could expedite the diagnosis of this condition. The delayed diagnosis of endometriosis presents a major issue, with patients often enduring about a decade of symptoms before receiving an official diagnosis and commencing targeted treatment. After the patient receives appropriate therapy, an app can prove invaluable in documenting the patient's response to the treatment.

Aside from diagnosis and monitoring, a patient app can serve various other beneficial purposes, including providing support, advice, tips, and additional information on symptoms and therapy to the patient.

The findings of this study suggest that a successful app for endometriosis management should offer more comprehensive features. One of the reasons for this is the complexity involved in managing endometriosis as a medical condition.

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.